Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | February 27, 2009 | March 04, 2009 |
| Assertio Holdings, Inc.ASRT · Entity 37706 | Director | March 14, 2024 | March 16, 2024 |
| Assertio Therapeutics, IncASRT · Entity 149352 | Director | May 07, 2019 | May 09, 2019 |
| GENELUX CorpGNLX · Entity 1116 | Director | June 16, 2026 | June 18, 2026 |
| Innoviva, Inc.INVA · Entity 4679 | Director | April 20, 2017 | April 24, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 27, 2009 · Filed March 04, 2009
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 132,176 |
Ending reported balance
After 2009-02-27 transaction · row 10
10 source rows · reconciled sequenceRow 1 · 2009-02-27 · Tax withholding · Disposed 6,813 · Balance 142,630 Row 2 · 2009-02-27 · Sale · Disposed 5,554 · Balance 137,076 Row 3 · 2009-02-27 · Sale · Disposed 1,300 · Balance 135,776 Row 4 · 2009-02-27 · Sale · Disposed 200 · Balance 135,576 Row 5 · 2009-02-27 · Sale · Disposed 200 · Balance 135,376 Row 6 · 2009-02-27 · Sale · Disposed 1,500 · Balance 133,876 Row 7 · 2009-02-27 · Sale · Disposed 300 · Balance 133,576 Row 8 · 2009-02-27 · Sale · Disposed 200 · Balance 133,376 Row 9 · 2009-02-27 · Sale · Disposed 700 · Balance 132,676 Row 10 · 2009-02-27 · Sale · Disposed 500 · Balance 132,176 |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 1,199 |
Reported balance
Holding disclosure · report date 2009-02-27 · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · Balance 1,199 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of February 26, 2009. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of February 26, 2009.
Assertio Holdings, Inc.
Report date March 14, 2024 · Filed March 16, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 188,251 |
Reported balance
After 2024-03-14 transaction · row 1
1 source rowRow 1 · 2024-03-14 · Sale · Disposed 10,251 · Balance 188,251 F1: The price reported is a weighted average sale price. The shares were sold in multiple same-way transactions on March 14, 2024 at prices ranging from $1.08 to $1.15 per share of common stock. If requested by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, the reporting person will provide full information regarding the number of shares of common stock sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average sale price. The shares were sold in multiple same-way transactions on March 14, 2024 at prices ranging from $1.08 to $1.15 per share of common stock. If requested by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, the reporting person will provide full information regarding the number of shares of common stock sold at each separate price.
Assertio Therapeutics, Inc
Report date May 07, 2019 · Filed May 09, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,340 |
Reported balance
After 2019-05-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-05-07 · Grant · Acquired 39,584 · Balance 49,340 F1: Restricted stock units that vest in full on the first anniversary of the grant date. F2: Since the date of the reporting person's last ownership report, he transferred 9,756 shares of the Registrant's common stock pursuant to a domestic relations order. The reporting person no longer reports these securities as beneficially owned by him. |
| Common StockSEC Table I · non-derivative | Direct | 80,590 |
Reported balance
After 2019-05-08 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2019-05-08 · Exercise / conversion · Acquired 31,250 · Balance 80,590 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2019-05-08 | Direct | 0 |
Reported balance
After 2019-05-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-05-08 · Exercise / conversion · Disposed 31,250 · Balance 0 F3: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock. F4: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units that vest in full on the first anniversary of the grant date.
F2: Since the date of the reporting person's last ownership report, he transferred 9,756 shares of the Registrant's common stock pursuant to a domestic relations order. The reporting person no longer reports these securities as beneficially owned by him.
F3: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock.
F4: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities.
GENELUX Corp
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 96,483 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 28,409 · Balance 96,483 F1: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.03 · Expires 2036-06-15 | Direct | 31,566 |
Reported balance
After 2026-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-16 · Grant · Acquired 31,566 · Balance 31,566 F2: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders.
F2: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders.
Innoviva, Inc.
Report date April 20, 2017 · Filed April 24, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 70,554 |
Reported balance
After 2017-04-20 transaction · row 1
1 source rowRow 1 · 2017-04-20 · Grant · Acquired 19,857 · Balance 70,554 F1: The Reporting Person was granted restricted stock units ("RSUs"). 100% of the RSUs will vest at the sooner of the next annual shareholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"). 100% of the RSUs will vest at the sooner of the next annual shareholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ChemoCentryx, Inc.
Report date October 20, 2022 · Filed October 24, 2022
Section 16 reporting ended · disclosed 2022-10-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 1
1 source rowRow 1 · 2022-10-20 · Disposition to issuer · Disposed 9,138 · Balance 0 F1: Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Shares," and each such share, a "Share") (other than any such Shares (i) held by the Company as treasury stock or owned by Parent or Merger Sub, (ii) held by any subsidiary of the Company or Parent (other than Merger Sub) or (iii) as to which appraisal rights have been properly exercised, F2: (Continued from Footnote 1) and not withdrawn, in accordance with the Delaware General Corporation Law) was thereupon canceled and converted into the right to receive $52.00 in cash, without interest (the "Merger Consideration"). As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any Shares. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $22.39 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-20 · Disposition to issuer · Disposed 8,342 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.06 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-20 · Disposition to issuer · Disposed 4,504 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $11.60 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-10-20 · Disposition to issuer · Disposed 12,287 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $12.94 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-10-20 · Disposition to issuer · Disposed 13,352 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $13.94 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-10-20 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-10-20 · Disposition to issuer · Disposed 15,723 · Balance 0 F4: At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Shares," and each such share, a "Share") (other than any such Shares (i) held by the Company as treasury stock or owned by Parent or Merger Sub, (ii) held by any subsidiary of the Company or Parent (other than Merger Sub) or (iii) as to which appraisal rights have been properly exercised,
F2: (Continued from Footnote 1) and not withdrawn, in accordance with the Delaware General Corporation Law) was thereupon canceled and converted into the right to receive $52.00 in cash, without interest (the "Merger Consideration"). As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any Shares.
F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
F4: At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,000 | $54.76 | $109,520.00 |
DisclosureSEC source: 0001104659-09-006507 · a4.xml · nonDerivative · entry 18 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,643 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,100 | $54.75 | $224,475.00 |
DisclosureSEC source: 0001104659-09-006507 · a4.xml · nonDerivative · entry 17 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,643 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 8,300 | $54.74 | $454,342.00 |
DisclosureSEC source: 0001104659-09-006507 · a4.xml · nonDerivative · entry 16 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,743 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,600 | $54.73 | $306,488.00 |
DisclosureSEC source: 0001104659-09-006507 · a4.xml · nonDerivative · entry 15 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,043 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,200 | $54.72 | $120,384.00 |
DisclosureSEC source: 0001104659-09-006507 · a4.xml · nonDerivative · entry 14 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,643 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,300 | $54.71 | $71,123.00 |
DisclosureSEC source: 0001104659-09-006507 · a4.xml · nonDerivative · entry 13 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,843 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $54.69 | $10,938.00 |
DisclosureSEC source: 0001104659-09-006507 · a4.xml · nonDerivative · entry 12 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,143 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,100 | $54.68 | $169,508.00 |
DisclosureSEC source: 0001104659-09-006507 · a4.xml · nonDerivative · entry 11 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,343 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,300 | $54.67 | $125,741.00 |
DisclosureSEC source: 0001104659-09-006507 · a4.xml · nonDerivative · entry 10 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,443 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 900 | $54.66 | $49,194.00 |
DisclosureSEC source: 0001104659-09-006507 · a4.xml · nonDerivative · entry 9 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,743 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $54.65 | $32,790.00 |
DisclosureSEC source: 0001104659-09-006507 · a4.xml · nonDerivative · entry 8 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,643 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 800 | $54.64 | $43,712.00 |
DisclosureSEC source: 0001104659-09-006507 · a4.xml · nonDerivative · entry 7 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,243 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,300 | $54.63 | $125,649.00 |
DisclosureSEC source: 0001104659-09-006507 · a4.xml · nonDerivative · entry 6 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,043 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,300 | $54.62 | $71,006.00 |
DisclosureSEC source: 0001104659-09-006507 · a4.xml · nonDerivative · entry 5 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,343 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,200 | $54.61 | $174,752.00 |
DisclosureSEC source: 0001104659-09-006507 · a4.xml · nonDerivative · entry 4 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,643 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 800 | $54.60 | $43,680.00 |
DisclosureSEC source: 0001104659-09-006507 · a4.xml · nonDerivative · entry 3 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,843 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,533 | $54.59 | $83,686.47 |
DisclosureSEC source: 0001104659-09-006507 · a4.xml · nonDerivative · entry 2 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,643 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $54.58 | $10,916.00 |
DisclosureSEC source: 0001104659-09-006507 · a4.xml · nonDerivative · entry 1 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,176 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 32,642 | $0.00 Strike: $46.34 | $0.00 |
DisclosureSEC source: 0001104659-09-006508 · a4.xml · derivative · entry 23 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,158 Underlying: Common shares · 32,642 shares Expires 2015-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option, including a replacement option feature, granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 10,856 | $0.00 Strike: $54.54 | $0.00 |
DisclosureSEC source: 0001104659-09-006508 · a4.xml · derivative · entry 22 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 10,856 shares Expires 2009-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option, including a replacement option feature, granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 55,333 | $0.00 Strike: $44.16 | $0.00 |
DisclosureSEC source: 0001104659-09-006508 · a4.xml · derivative · entry 21 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,667 Underlying: Common shares · 55,333 shares Expires 2016-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option, including a replacement option feature, granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 55,333 | $54.74 | $3,028,878.62 |
DisclosureSEC source: 0001104659-09-006508 · a4.xml · nonDerivative · entry 19 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,143 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 32,642 | $46.34 | $1,512,630.28 |
DisclosureSEC source: 0001104659-09-006508 · a4.xml · nonDerivative · entry 18 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 10,856 | $54.54 | $592,086.24 |
DisclosureSEC source: 0001104659-09-006508 · a4.xml · nonDerivative · entry 17 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 55,333 | $44.16 | $2,443,505.28 |
DisclosureSEC source: 0001104659-09-006508 · a4.xml · nonDerivative · entry 16 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,978 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,500 | $55.34 | $83,010.00 |
DisclosureSEC source: 0001104659-09-006508 · a4.xml · nonDerivative · entry 15 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,645 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,300 | $55.33 | $293,249.00 |
DisclosureSEC source: 0001104659-09-006508 · a4.xml · nonDerivative · entry 14 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,145 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,642 | $55.32 | $90,835.44 |
DisclosureSEC source: 0001104659-09-006508 · a4.xml · nonDerivative · entry 13 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,445 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,000 | $55.30 | $55,300.00 |
DisclosureSEC source: 0001104659-09-006508 · a4.xml · nonDerivative · entry 12 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,087 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,000 | $55.29 | $165,870.00 |
DisclosureSEC source: 0001104659-09-006508 · a4.xml · nonDerivative · entry 11 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,087 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,100 | $55.28 | $171,368.00 |
DisclosureSEC source: 0001104659-09-006508 · a4.xml · nonDerivative · entry 10 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,087 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,200 | $55.27 | $66,324.00 |
DisclosureSEC source: 0001104659-09-006508 · a4.xml · nonDerivative · entry 9 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,187 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,500 | $55.26 | $82,890.00 |
DisclosureSEC source: 0001104659-09-006508 · a4.xml · nonDerivative · entry 8 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,387 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,400 | $55.25 | $77,350.00 |
DisclosureSEC source: 0001104659-09-006508 · a4.xml · nonDerivative · entry 7 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,887 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 500 | $55.24 | $27,620.00 |
DisclosureSEC source: 0001104659-09-006508 · a4.xml · nonDerivative · entry 6 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,287 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,400 | $55.23 | $132,552.00 |
DisclosureSEC source: 0001104659-09-006508 · a4.xml · nonDerivative · entry 5 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,787 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,300 | $55.22 | $237,446.00 |
DisclosureSEC source: 0001104659-09-006508 · a4.xml · nonDerivative · entry 4 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,187 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,800 | $55.21 | $265,008.00 |
DisclosureSEC source: 0001104659-09-006508 · a4.xml · nonDerivative · entry 3 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,487 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,000 | $55.20 | $55,200.00 |
DisclosureSEC source: 0001104659-09-006508 · a4.xml · nonDerivative · entry 2 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,287 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 02:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,000 | $54.88 | $54,880.00 |
DisclosureSEC source: 0001104659-09-006508 · a4.xml · nonDerivative · entry 1 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,287 Read SEC document |
| February 02, 2009 Filed Feb 18, 2009 22:00 UTC Amendment | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 32,642 | $46.34 | $1,512,630.28 |
DisclosureSEC source: 0001104659-09-010511 · a4a.xml · nonDerivative · entry 18 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2009 Filed Feb 18, 2009 22:00 UTC Amendment | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 10,856 | $54.54 | $592,086.24 |
DisclosureSEC source: 0001104659-09-010511 · a4a.xml · nonDerivative · entry 17 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2009 Filed Feb 18, 2009 22:00 UTC Amendment | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 55,333 | $44.16 | $2,443,505.28 |
DisclosureSEC source: 0001104659-09-010511 · a4a.xml · nonDerivative · entry 16 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,978 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2009 Filed Feb 18, 2009 22:00 UTC Amendment | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,500 | $55.34 | $83,010.00 |
DisclosureSEC source: 0001104659-09-010511 · a4a.xml · nonDerivative · entry 15 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,645 Read SEC document |
| February 02, 2009 Filed Feb 18, 2009 22:00 UTC Amendment | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,300 | $55.33 | $293,249.00 |
DisclosureSEC source: 0001104659-09-010511 · a4a.xml · nonDerivative · entry 14 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,145 Read SEC document |
| February 02, 2009 Filed Feb 18, 2009 22:00 UTC Amendment | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,642 | $55.32 | $90,835.44 |
DisclosureSEC source: 0001104659-09-010511 · a4a.xml · nonDerivative · entry 13 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,445 Read SEC document |
| February 02, 2009 Filed Feb 18, 2009 22:00 UTC Amendment | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,000 | $55.30 | $55,300.00 |
DisclosureSEC source: 0001104659-09-010511 · a4a.xml · nonDerivative · entry 12 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,087 Read SEC document |
| February 02, 2009 Filed Feb 18, 2009 22:00 UTC Amendment | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,000 | $55.29 | $165,870.00 |
DisclosureSEC source: 0001104659-09-010511 · a4a.xml · nonDerivative · entry 11 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,087 Read SEC document |
| February 02, 2009 Filed Feb 18, 2009 22:00 UTC Amendment | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,100 | $55.28 | $171,368.00 |
DisclosureSEC source: 0001104659-09-010511 · a4a.xml · nonDerivative · entry 10 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,087 Read SEC document |
| February 02, 2009 Filed Feb 18, 2009 22:00 UTC Amendment | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,200 | $55.27 | $66,324.00 |
DisclosureSEC source: 0001104659-09-010511 · a4a.xml · nonDerivative · entry 9 Tyree James L · CIK 0001324991 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,187 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.